The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
Abstract N-terminal HSP90 inhibitors in development have had issues arising from heat shock response (HSR) induction and off-target effects. We sought to investigate the capacity of NCT-58, a rationally-synthesized C-terminal HSP90 inhibitor, to kill trastuzumab-resistant HER2-positive breast cancer...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Publishing Group
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/5abd2556d6fa4f7bb936d8f0108b8169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|